Journal of Cardiac Failure
Volume 12, Issue 6 , Pages 446-451 , August 2006

Clopidogrel Is Associated With a Lesser Increase in NT-proBNP When Compared to Aspirin in Patients With Ischemic Heart Failure

Received 1 February 2006 ,Revised 14 April 2006 ,Accepted 17 April 2006.

References 

  1. Al-Khadra A, Salem D, Rand W, Udelsonm J, Smith J, Konstam MA. Antiplatlet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol. 1998;31:419–425
  2. Cleland J, Findlay I, Jafri S, Suton G, Falk R, Bulpitt C, et al. The Warfarin/Aspirin Study in Heart Failure (WASH): a randomized Trial Comparing Antithrombotic Strategies for Patients with Heart Failure. Am Heart J. 2004;138:157–164
  3. Konstam MA. Aspirin and heart failure: square evidence meets a round patient. Congest Heart Fail. 2003;9:1616–1617
  4. Hall D, Zeilter H, Rudolph W. Counteraction of the vasodilatatory effect of enalapril by aspirin in severe heart failure. J Am Coll Cardiol. 1992;20:1549–1555
  5. Moertl D, Berger R, Huelsmann M, Bojic A, Pacher R. Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. Eur J Heart Fail. 2005;7:1156–1163
  6. Meune C, Mahe I, Solal A, et al. Comparative effect of aspirin and clopidogrel on arterial function in CHF. Int J Cardiol. 2006;106:61–66
  7. Gardner R, Ozalp F, Murday A, Robb S, McDonagh T. N-terminal pro-brain natriuretic peptide: A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003;24:1735–1743
  8. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005;330:625–634
  9. Karl J, Borgia A, Gallusser A. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest. 1999;230(Suppl):177–181
  10. Melzi d'Eril G, Tagnochetti T, Nauti A, et al. Biological Variation of N-Terminal Pro-Brain Natriuretic Peptide in Healthy Individuals. Clin Chem. 2003;49:1554–1555
  11. Massie B. Aspirin use in chronic heart failure: what should we recommend to the practitioner?. J Am Coll Cardiol. 2005;46:936–939
  12. Brunner La Rocca H, Weilenmann D, Kiowski W. Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Am Heart J. 1999;138:654–662
  13. Yoshimura M, Yasue H, Tanaka H. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J. 1994;72:528–533
  14. Yoshimura M, Mizuno Y, Nakayama M, et al. B-natriuretic peptide as a marker of effects of enalapril in patients with heart failure. Am J Med. 2002;112:716–720
  15. van Veldhuisen D, Genth-Zotz S, Brouwer J. High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol. 1998;32:1811–1818
  16. Spaulding C, Charbonnier B, Cohen-Solal A. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of double-blind, randomized cooperative trial. Circulation. 1998;98:757–765
  17. Davie A, Love M, McMurray J. Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. Clin Pharmacol Ther. 2000;67:530–537
  18. Meune C, Mahe I, Mourad J, et al. Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect. Eur J Heart Fail. 2003;5:271–279
  19. Baur L, Schipperheyn J, van der Laarse A, et al. Combining salicylate and enalapril in patients with coronary artery disease and heart failure. Br Heart J. 1995;73:227–236
  20. Vaughan D. Endothelial function, fibrinolysis, and angiotensin-converting enzyme inhibition. Clin Cardiol. 1997;20:34–37
  21. Rigger G, Kahles H, Elsner D, Kromer E, Kochsiek K. Effects of acetylsalicylic acid on renal function in patients with chronic heart failure. Am J Med. 1991;90:571–575
  22. Guazzi M, Marenzi G, Alimento M. Improvement of alveolo-capilary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effects of aspirin. Circulation. 1997;95:1930–1936
  23. Wu A, Smith A, Wieczorek S, et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol. 2003;92:628–631
  24. Latini R, Masson S, Anand I, et al. for the Val-HeFT Investigators Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2002;106:2454–2458
  25. Anand IS, Fisher LD, Chiang Y-T, et al. for the Val-HeFT Investigators Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107:1278–1283
  26. Massie B, Krol W, Amon S. The warfarin and antiplatelet therapy in heart failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail. 2004;10:101–112

PII: S1071-9164(06)00214-4

doi: 10.1016/j.cardfail.2006.04.003

Journal of Cardiac Failure
Volume 12, Issue 6 , Pages 446-451 , August 2006

Article Tools

* Image Usage & Resolution